Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval

IF 7.9 1区医学 Q1 IMMUNOLOGY

Journal of autoimmunity Pub Date : 2024-06-05 DOI:10.1016/j.jaut.2024.103264

Xiaoqian Xu , Tongtong Meng , Lichen Shi , Weijia Duan , Junqi Niu , Huiguo Ding , Wen Xie , Lu Zhou , Bangmao Wang , Jie Li , Lingyi Zhang , Yu Wang , Xiaojuan Ou , Xinyan Zhao , Hong You , Jidong Jia , Yuanyuan Kong

{"title":"Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval","authors":"Xiaoqian Xu , Tongtong Meng , Lichen Shi , Weijia Duan , Junqi Niu , Huiguo Ding , Wen Xie , Lu Zhou , Bangmao Wang , Jie Li , Lingyi Zhang , Yu Wang , Xiaojuan Ou , Xinyan Zhao , Hong You , Jidong Jia , Yuanyuan Kong","doi":"10.1016/j.jaut.2024.103264","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & aims</h3><p>Epidemiology of primary sclerosing cholangitis (PSC) is lacking in China. We aimed to estimate the period prevalence and depict the clinical features of PSC in China.</p></div><div><h3>Methods</h3><p>We identified and included PSC cases between 2000 and 2023 from two sources: electronic medical records (EMR) and systematical literature retrieval (SLR). The period prevalence of PSC was estimated by the multiplier method. Rate ratios (RRs) for PSC prevalence in relation to macroeconomic indicators were calculated by the negative binomial regression model.</p></div><div><h3>Results</h3><p>A total of 1358 PSC cases were retrieved from 299 hospitals (162 from EMR and 1196 from SLR). Males accounted for 55.7 % of the PSC cases and 25.7 % had concomitant inflammatory bowel disease (IBD). The estimated period prevalence of PSC from 2000 to 2023 was 2.36 (95 % CI: 1.82, 3.34) per 100,000. Males had a numerically higher PSC prevalence than females (2.56, 95 % CI: 1.97, 3.63 vs. 2.14, 95 % CI: 1.65, 3.04 per 100,000). The highest prevalence of PSC was in East China at 4.87 (95 % CI: 3.44, 7.18) per 100,000, followed by North China at 2.94 (95 % CI: 2.33, 3.74) per 100,000, and the lowest in South China at 0.92 (95 % CI: 0.66, 1.30) per 100,000. Regional per capita GDP (RR 1.65, 95 % CI: 1.03, 2.65) and healthcare expenditure (RR 1.94, 95 % CI: 1.13, 3.38) were identified to be associated with PSC prevalence.</p></div><div><h3>Conclusion</h3><p>Our study showed the estimated PSC prevalence varied within China, but was generally lower than that in Western countries.</p></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"147 ","pages":"Article 103264"},"PeriodicalIF":7.9000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of autoimmunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0896841124000982","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background & aims

Epidemiology of primary sclerosing cholangitis (PSC) is lacking in China. We aimed to estimate the period prevalence and depict the clinical features of PSC in China.

Methods

We identified and included PSC cases between 2000 and 2023 from two sources: electronic medical records (EMR) and systematical literature retrieval (SLR). The period prevalence of PSC was estimated by the multiplier method. Rate ratios (RRs) for PSC prevalence in relation to macroeconomic indicators were calculated by the negative binomial regression model.

Results

A total of 1358 PSC cases were retrieved from 299 hospitals (162 from EMR and 1196 from SLR). Males accounted for 55.7 % of the PSC cases and 25.7 % had concomitant inflammatory bowel disease (IBD). The estimated period prevalence of PSC from 2000 to 2023 was 2.36 (95 % CI: 1.82, 3.34) per 100,000. Males had a numerically higher PSC prevalence than females (2.56, 95 % CI: 1.97, 3.63 vs. 2.14, 95 % CI: 1.65, 3.04 per 100,000). The highest prevalence of PSC was in East China at 4.87 (95 % CI: 3.44, 7.18) per 100,000, followed by North China at 2.94 (95 % CI: 2.33, 3.74) per 100,000, and the lowest in South China at 0.92 (95 % CI: 0.66, 1.30) per 100,000. Regional per capita GDP (RR 1.65, 95 % CI: 1.03, 2.65) and healthcare expenditure (RR 1.94, 95 % CI: 1.13, 3.38) were identified to be associated with PSC prevalence.

Conclusion

Our study showed the estimated PSC prevalence varied within China, but was generally lower than that in Western countries.

查看原文本刊更多论文

中国原发性硬化性胆管炎的发病率和临床概况：电子病历数据和系统文献检索

背景& 目的中国缺乏原发性硬化性胆管炎（PSC）的流行病学研究。方法我们从电子病历（EMR）和系统文献检索（SLR）两个来源发现并纳入了2000年至2023年间的原发性硬化性胆管炎病例。我们采用乘数法估算了PSC在不同时期的患病率。通过负二项回归模型计算了与宏观经济指标相关的 PSC 患病率比率（RRs）。结果从 299 家医院共检索到 1358 例 PSC 病例（162 例来自电子病历，1196 例来自系统文献检索）。男性占 PSC 病例的 55.7%，25.7% 伴有炎症性肠病 (IBD)。据估计，2000 年至 2023 年期间，PSC 的患病率为每 10 万人 2.36 例（95 % CI：1.82, 3.34）。男性的 PSC 患病率高于女性（2.56，95 % CI：1.97, 3.63 vs. 2.14，95 % CI：1.65, 3.04/100,000）。华东地区 PSC 患病率最高，为每 10 万人 4.87 例（95 % CI：3.44 例，7.18 例），其次是华北地区，为每 10 万人 2.94 例（95 % CI：2.33 例，3.74 例），华南地区最低，为每 10 万人 0.92 例（95 % CI：0.66 例，1.30 例）。地区人均 GDP（RR 1.65，95 % CI：1.03, 2.65）和医疗支出（RR 1.94，95 % CI：1.13, 3.38）与 PSC 患病率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of autoimmunity 医学-免疫学

CiteScore

27.90

自引率

1.60%

发文量

117

审稿时长

17 days

期刊介绍： The Journal of Autoimmunity serves as the primary publication for research on various facets of autoimmunity. These include topics such as the mechanism of self-recognition, regulation of autoimmune responses, experimental autoimmune diseases, diagnostic tests for autoantibodies, as well as the epidemiology, pathophysiology, and treatment of autoimmune diseases. While the journal covers a wide range of subjects, it emphasizes papers exploring the genetic, molecular biology, and cellular aspects of the field. The Journal of Translational Autoimmunity, on the other hand, is a subsidiary journal of the Journal of Autoimmunity. It focuses specifically on translating scientific discoveries in autoimmunity into clinical applications and practical solutions. By highlighting research that bridges the gap between basic science and clinical practice, the Journal of Translational Autoimmunity aims to advance the understanding and treatment of autoimmune diseases.